CN107114764A - A kind of new application of composition - Google Patents
A kind of new application of composition Download PDFInfo
- Publication number
- CN107114764A CN107114764A CN201710223954.2A CN201710223954A CN107114764A CN 107114764 A CN107114764 A CN 107114764A CN 201710223954 A CN201710223954 A CN 201710223954A CN 107114764 A CN107114764 A CN 107114764A
- Authority
- CN
- China
- Prior art keywords
- root
- radix astragali
- kudzu vine
- white mulberry
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 239000009636 Huang Qi Substances 0.000 claims abstract description 85
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 82
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 82
- 240000000249 Morus alba Species 0.000 claims abstract description 81
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 81
- 230000002265 prevention Effects 0.000 claims abstract description 45
- 208000008589 Obesity Diseases 0.000 claims abstract description 36
- 235000020824 obesity Nutrition 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 230000036541 health Effects 0.000 claims abstract description 21
- 241000219780 Pueraria Species 0.000 claims description 6
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 4
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 4
- 235000021286 stilbenes Nutrition 0.000 claims description 4
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 241000700159 Rattus Species 0.000 description 68
- 230000001225 therapeutic effect Effects 0.000 description 34
- 210000004185 liver Anatomy 0.000 description 31
- 230000003449 preventive effect Effects 0.000 description 23
- 150000002632 lipids Chemical class 0.000 description 21
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 238000010586 diagram Methods 0.000 description 19
- 210000003486 adipose tissue brown Anatomy 0.000 description 18
- 150000003626 triacylglycerols Chemical class 0.000 description 18
- 230000037396 body weight Effects 0.000 description 17
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 230000037182 bone density Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 201000010063 epididymitis Diseases 0.000 description 9
- 229940002661 lipitor Drugs 0.000 description 9
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 6
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 6
- 229930186217 Glycolipid Natural products 0.000 description 6
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 6
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101100220687 Mus musculus Cidea gene Proteins 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 238000010603 microCT Methods 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical group C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 3
- 101000686942 Homo sapiens Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 210000000593 adipose tissue white Anatomy 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000009923 sugaring Methods 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102100024594 Histone-lysine N-methyltransferase PRDM16 Human genes 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001593 brown adipocyte Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- MUUDYSFWQUSAOO-UHFFFAOYSA-N cudraflavone C Chemical compound CC(C)=CCC=1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=1C1=CC=C(O)C=C1O MUUDYSFWQUSAOO-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- SYFDWXWLRGHYAJ-HXUWFJFHSA-N Cyclomulberrin Natural products O=C1c2c(O)cc(O)c(C/C=C(\C)/C)c2OC=2c3c(O[C@H](/C=C(\C)/C)C1=2)cc(O)cc3 SYFDWXWLRGHYAJ-HXUWFJFHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101100521059 Homo sapiens PRDM16 gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 101800001026 Irisin Proteins 0.000 description 1
- PWHGUSAQRRPLSJ-IBGZPJMESA-N Isocyclomulberrin Natural products O=C1c2c(O)c(C/C=C(\C)/C)c(O)cc2OC=2c3c(O[C@@H](/C=C(\C)/C)C1=2)cc(O)cc3 PWHGUSAQRRPLSJ-IBGZPJMESA-N 0.000 description 1
- 240000006859 Jasminum officinale Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- UWQYBLOHTQWSQD-UHFFFAOYSA-N Mulberrin Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2CC=C(C)C)=O)=C1OC=2C1=CC=C(O)C=C1O UWQYBLOHTQWSQD-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 101150063753 PRDM16 gene Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000777393 Rattus norvegicus C-C motif chemokine 2 Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical group O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- SYFDWXWLRGHYAJ-UHFFFAOYSA-N cyclomulberrin Chemical compound C12=CC=C(O)C=C2OC(C=C(C)C)C(C2=O)=C1OC1=C2C(O)=CC(O)=C1CC=C(C)C SYFDWXWLRGHYAJ-UHFFFAOYSA-N 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- XFFOMNJIDRDDLQ-UHFFFAOYSA-N morusin Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XFFOMNJIDRDDLQ-UHFFFAOYSA-N 0.000 description 1
- WUBUWBUVAKMGCO-UHFFFAOYSA-N morusin Natural products CC(=CCC1=C(Cc2c3C=CC(C)(C)Oc3cc(O)c2C1=O)c4ccc(O)cc4O)C WUBUWBUVAKMGCO-UHFFFAOYSA-N 0.000 description 1
- XIWCDUHPYMOFIL-UHFFFAOYSA-N mulberrochromene Natural products O1C2=CC=3OC(C)(C)C=CC=3C(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XIWCDUHPYMOFIL-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 108700028277 rat PRDM16 Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of purposes of composition in food, medicine and the health products for preparing prevention or treatment obesity or hyperhomocysteinemiainjury, wherein, the composition includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=(1~2)：(1~2)：(0~2).Present invention firstly discovers that comprising the Radix Astragali, the root of kudzu vine and root bark of white mulberry composition can effective for obesity prevention and treatment, significant effect can be produced.It has also been found that this composition can effectively treat hyperhomocysteinemiainjury, the treatment for obesity and hyperhomocysteinemiainjury provides new selection.
Description
Technical field
The present invention relates to a kind of new application of the composition comprising the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, more particularly to said composition
Purposes in preventing or treating food, medicine and the health products of obesity or hyperhomocysteinemiainjury.
Background technology
The Radix Astragali, also known as continuous stilbene, its main active is Astragaloside IV, with suppression metabolic syndrome, delays cardiac muscle to lack
Blood Myocardial lesion and improve the effect such as heart function, modern medicine study shows, the Radix Astragali have enhancing body's immunity, liver protection,
Diuresis, anti-aging, resisting stress, decompression and wide antibacterial action.Jishengshenqiwan albuminuria can be eliminated, strengthens myocardial contraction
Power, adjusts blood-sugar content.The Radix Astragali can not only coronary artery dilator, improve myocardial blood supply, improve immunologic function, and can delay
The process of cell ageing.
The root of kudzu vine, is the dry root of legume pueraria lobata, practises and claims elegant jessamine.Chief active position is general flavone in the root of kudzu vine, wherein
Puerarin is one of its main active.Puerarin has hypoglycemic, lipid-loweringing, improves Insulin Resistance, and decompression, expansion
Open coronary artery, improve myocardial ischemia, anti anoxia reperfusion injury, protection endothelial function to improve Hemodynamics, suppress blood
Platelet aggregation etc. a variety of cardiovascular protective effects, therefore Puerarin be widely used in clinical treatment fro diabetic coronary heart disease and
A variety of angiocardiopathies.
The root bark of white mulberry is the dry root skin of moraceae plants mulberry.It contains flavones ingredient:Mulberrin, mulberrochromene, cyclomulberrin etc..
Separated in the root bark of white mulberry and confirm that blood sugar reducing component takes off dioxy imido grpup grape alcohol and MoranA sugar reducing substances, through overtesting,
Verified MoranA has dose-dependent hypoglycemic effect to the hyperglycaemia mouse of model induced by alloxan.
Obesity is a kind of common metabolic disease.It is reported that the whole world in 2008 have 200,000,000 adult males, 3 hundred million one-tenth
Year, women suffered from obesity.The year two thousand thirty is estimated, whole world obesity number will be up to 1,000,000,000.Obesity can make hypertension, glycosuria
The incidence of disease and the death rate of disease and cardiovascular and cerebrovascular disease etc. are dramatically increased, it has also become the major issue of harm global human health it
One, the focus as social extensive concern.Fat prevention and treatment have turned into the challenge that modern medicine faces.2008
Year, only the U.S. is used for just up to 147,000,000,000 dollars of fat medical expense.According to rich think of data statistics, global slimming drugs city in 2012
Field scale is 15.6 hundred million dollars, wherein 30.5 hundred million yuan of China's slimming drugs retail market scale, slimming drugs (prescription medicine) market scale
For 16.8 hundred million yuan.70,000,000,000 are up to by the following possible whole world of present market prediction, wherein nearly 10,000,000,000 yuan of China.
Homocysteine (High homocysteine, HHcy) mass formed by blood stasis is homocysteine
(homocysteine, Hcy) raises a kind of metabolic disease formed in blood, and HHcy mass formed by blood stasis is the danger of a variety of diseases
The dangerous factor, it is however generally that, homocysteine level rise can make angiocardiopathy mortality prediction increase by 4~6 times, there is research
It has been shown that, then increases by 60%, women then increases by 80% when the total Hcy levels of blood plasma often raise 5umol/L risk of coronary heart disease males,
And severe plasma homocysteine mostly occurs in the crowd with Other diseases, particularly diabetes, coronary artery are athero- hard
The diseases such as change, senile dementia, apoplexy, venous embolism, these patient's plasma homocysteine levels are apparently higher than normal person.
The Radix Astragali, the root of kudzu vine and the root bark of white mulberry are combined for treating diabetes, hyperlipoprotememia by certain ratio
Report, but by the Radix Astragali, the root of kudzu vine and the root bark of white mulberry be used for treat obesity and hyperhomocysteinemiainjury, at present also do not have appoint
What is studied and reported.
The content of the invention
On the one hand, it is an object of the invention to overcome above-mentioned the deficiencies in the prior art part there is provided comprising the Radix Astragali, Pueraria lobota
Purposes of the composition of root and the root bark of white mulberry in food, medicine and the health products for preparing prevention or treatment obesity.
The technical solution adopted by the present invention is：A kind of composition is in food, the medicine for preparing prevention or treatment obesity
Purposes in thing and health products, wherein, the composition includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the Radix Astragali, the root of kudzu vine and Sang Bai
The mass ratio of skin is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=(1~2)：(1~2)：(0~2).
Present inventor has found by numerous studies and experiment, the Radix Astragali of special ratios relation as described above, the root of kudzu vine and
The composition of root bark of white mulberry composition, has especially significant effect in terms of standby prevention or treatment obesity.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=2:1:1.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=1:2:1.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=1:1:2.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=1:1:1.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=2:1:0.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the composition prevents by reducing the accumulation of the white adipose in obesity or treats obesity
Disease.
As composition of the present invention in food, medicine and the health products for preparing prevention or treatment obesity
The preferred embodiment of purposes, the composition can reduce homocysteine caused by obesity and raise.
On the other hand, present invention also offers a kind of composition for preparing prevention or treatment homocysteine blood
Purposes in food, medicine and the health products of disease, wherein, the composition includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the Huang
The mass ratio of stilbene, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：The root bark of white mulberry=(1~2)：(1~2)：(0~2).
Present inventor has found by numerous studies and experiment, the Radix Astragali of special ratios relation as described above, the root of kudzu vine and
The composition of root bark of white mulberry composition, has especially significant effect in terms of standby prevention or treatment hyperhomocysteinemiainjury.
As composition of the present invention in food, the medicine for preparing prevention or treatment hyperhomocysteinemiainjury
With the preferred embodiment of the purposes in health products, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：Sang Bai
Skin=2:1:1.
As composition of the present invention in food, the medicine for preparing prevention or treatment hyperhomocysteinemiainjury
With the preferred embodiment of the purposes in health products, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：Sang Bai
Skin=1:2:1.
As composition of the present invention in food, the medicine for preparing prevention or treatment hyperhomocysteinemiainjury
With the preferred embodiment of the purposes in health products, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：Sang Bai
Skin=1:1:2.
As composition of the present invention in food, the medicine for preparing prevention or treatment hyperhomocysteinemiainjury
With the preferred embodiment of the purposes in health products, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：Sang Bai
Skin=1:1:1.
As composition of the present invention in food, the medicine for preparing prevention or treatment hyperhomocysteinemiainjury
With the preferred embodiment of the purposes in health products, the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：Sang Bai
Skin=2:1:0.
Present invention firstly discovers that the composition comprising the Radix Astragali, the root of kudzu vine and the root bark of white mulberry can effective for obesity prevention and
Treatment, can produce significant effect.It has also been found that can effectively treat high same comprising the Radix Astragali, the root of kudzu vine and root bark of white mulberry composition
Type cysteinaemia, the treatment for obesity and hyperhomocysteinemiainjury provides new selection.
Brief description of the drawings
The model group rats (HFD groups) that Fig. 1 is obtained after being fed for the high lipid food through week for 7 weeks and normal rats (SD
Group) body weight and FPG, TC, TG, LDL-C level comparison diagram.
During Fig. 2 is preventive administration and therapeutic, the changes of weight comparison diagram of each group rat different times.
During Fig. 3 is preventive administration and therapeutic, the dietary amount comparison diagram of each group rat.
Fig. 4 is preventive administration after 7 weeks, each group rat FPG, TC, TG, LDL-C level change comparison diagram.
Fig. 5 is therapeutic after 9 weeks, each group rat FPG, TC, TG, LDL-C level change comparison diagram.
Fig. 6 is preventive administration after 12 weeks, each group rat FPG, TC, TG, LDL-C level change comparison diagram.
Fig. 7 is therapeutic after 14 weeks, each group rat FPG, TC, TG, LDL-C level change comparison diagram.
Fig. 8 preventive administrations 15 weeks and therapeutic are homogenized liver, each group rats'liver obtained after testing after 15 weeks
Dirty middle homocysteine level comparison diagram.
Fig. 9 is preventive administration 15 weeks and therapeutic after 15 weeks, homogenate liver, each group rat obtained after testing
The horizontal comparison diagram of glutamyl transpeptidase in liver.
Figure 10 is preventive administration 15 weeks and therapeutic after 15 weeks, and homogenate liver, each group obtained after testing is big
Lipid (TC, TG) horizontal comparison diagram in mouse liver.
Figure 11 is preventive administration 15 weeks and therapeutic after 15 weeks, each group rat hepatocytes progress oil red O stain
Steatosis comparison diagram afterwards.
Figure 12 is preventive administration 15 weeks and therapeutic after 15 weeks, the brown fat and epididymal adipose tissues of each group rat
The ratio between comparison diagram.
Figure 13 is preventive administration 15 weeks and therapeutic after 15 weeks, the brown fat and perirenal fat of each group rat
The ratio between comparison diagram.
Figure 14 is therapeutic after 15 weeks, the bone weight coefficient ratio comparison diagram of each group rat.
Figure 15 is that the micro-CT scanning figures that body scan is obtained are carried out to live body rat using Latheta LCT200.
Figure 16 is preventive administration after 14 weeks, the white adipose content balance figure in each group rat live body；
Figure 17 is preventive administration after 14 weeks, the fat content comparison diagram in each group rat liver.
Figure 18 is preventive administration after 14 weeks, each group rat femur cortical bone density, cancellous bone density, the contrast of total bone density
Figure.
Figure 19 is therapeutic after 12 weeks, each group diabetes rat UCP-1 expression quantity comparison diagrams.
Figure 20 is therapeutic after 12 weeks, each group diabetes rat Cidea expression quantity comparison diagrams.
Figure 21 is therapeutic after 12 weeks, each group diabetes rat MCP-1 expression quantity comparison diagrams.
Figure 22 is therapeutic after 12 weeks, each group diabetes rat PRDM16 transcription factor mrna expression amount comparison diagrams.
Embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with the drawings and specific embodiments pair
The present invention is described further.
Given in composition 1~composition of embodiment embodiment 5 available for preparation prevention or treatment obesity or high same
The example of the composition comprising the Radix Astragali, the root of kudzu vine and the root bark of white mulberry of the food of type cysteinaemia, medicine and health products.
Composition embodiment 1
A kind of composition, it includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is
The Radix Astragali：The root of kudzu vine：The root bark of white mulberry=2:1:1.
Composition embodiment 2
A kind of composition, it includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is
The Radix Astragali：The root of kudzu vine：The root bark of white mulberry=1:2:1.
Composition embodiment 3
A kind of composition, it includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is
The Radix Astragali：The root of kudzu vine：The root bark of white mulberry=1:1:2.
Composition embodiment 4
A kind of composition, it includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is
The Radix Astragali：The root of kudzu vine：The root bark of white mulberry=1:1:1.
Composition embodiment 5
A kind of composition, it includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is
The Radix Astragali：The root of kudzu vine：The root bark of white mulberry=2:1:0.
Illustrate that the composition comprising the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is preventing or treated fat below by way of specific embodiment
Purposes in disease or homocysteine.
Embodiment 1 includes application of the composition of the Radix Astragali, the root of kudzu vine, the root bark of white mulberry in prevention and treatment obesity
1. experiment packet
This experiment includes composition (HQS) prevention administration and therapeutic administratp two parts.Healthy answering property of male SD rat is raised
After one week, normal group (SD) and modeling group are randomly divided into, normal group is fed using basal feed, and modeling group is fed using high lipid food
Support, free water and feed, while it is model group (HFD) to choose 10 modeling group rats.Composition prevention administration：By modeling group
Rat is randomly divided into HQS-L-composition low dose group (1.2g/kg.d), HQS-H-composition high dose group (2.4g/
Kg.d), every group 8, while modeling is administered simultaneously.Composition treatment is administered：After the continuous high fat diet of modeling group rat 7 weeks,
Modeling group body weight is apparently higher than normal group (the SD rats of feeding basal feed), and modeling group FPG, TC, TG, LDL-C level is also bright
It is aobvious to be higher than normal group, show now model success, with significant difference, specifically as shown in Figure 1.Select more than normal rat
The rat of body weight 20% is obese rat model, is randomly divided into HQS-L-composition low dose group (1.2g/kg.d), HQS-H
- composition high dose group (2.4g/kg.d), Lipitor positive drug group (Lipitor, 2mg/kg), every group 8, high fat diet 7
Zhou Houzai starts administration.Normal group and model group rats give the physiological saline of equivalent respectively, and each administration group gives corresponding reagent,
Once a day.Wherein, the administration of composition high and low dose group is fat-reducing liver-protecting composition of the invention, the wherein Radix Astragali：The root of kudzu vine：
The mass ratio of the root bark of white mulberry is 1:2:1.
2. medication
2.1 preventive administrations (prevention group is administered when high lipid food is fed)；
2.1.1 dosage is set
The dosage of composition low dosage (HQS-L) and composition high dose (HQS-H) is set to be tried according to the multiple drug effect of early stage
Test set effective dose, dosage be respectively 1.2g/kg.d and
2.4g/kg.d。
2.1.2 medication
Once a day, successive administration 15 weeks.
2.2 therapeutics (treatment group is that high fat diet starts administration again after 7 weeks).
2.2.1 dosage is set
The dosage of composition low dosage (HQS-L) and composition high dose (HQS-H) is set to be tried according to the multiple drug effect of early stage
Test set effective dose, dosage be respectively 1.2g/kg.d and
2.4g/kg.d.Lipitor dosage is that dosage is 2g/kg.d according to set by people's clinical equivalent dosage.
2.2.2 medication
Once a day, successive administration 15 weeks.
3. experimental working technique
3.1 body weight
In experimentation situations such as observation each group rat body weight change daily, feed, fur, activity, body weight is recorded weekly
Change.
3.2 glycolipid biochemical indicators
Prevention administration：In 7 weekends and 12 weekends of administration are administered, Rat Fast can't help water 12h, etherization, eyeground vein
Clump takes blood, and anticoagulant heparin, 4 DEG C of centrifugations (3000r/min, 15min) point take blood plasma, determine fasting blood-glucose (FPG), cholesterol
(TC), triglycerides (TG), low-density lipoprotein (LDL-C)；
Therapeutic administratp：In 9 weekends and 14 weekends of administration are administered, Rat Fast can't help water 12h, etherization, eyeground vein
Clump takes blood, and anticoagulant heparin, 4 DEG C of centrifugations (3000r/min, 15min) point take blood plasma, determine FPG, TC, TG, LDL-C.
3.3 experiment materials and organ coefficient
At the end of experiment, each group rat weight, and (0.35ml/100g body weight) is injected intraperitoneally with 10% chloraldurate, will
Lie on the back and be fixed on dissection plate after rat anesthesia, rat anesthesia, carry out abdominal aortic blood execution, obtain blood specimen a part of quiet
Put after 2h 3000r/min and centrifuge 30min and obtain serum, a part is whole blood, and dispense that to be placed in -20 DEG C of refrigerators standby.It is rapid to take out
The organs and tissues such as the heart, liver, spleen, lung, kidney, epididymal adipose, perirenal adipose tissue, brown adipose tissue, femur, weigh, point
Dress, places -80 DEG C of freezen protectives of cryopreservation tube.Calculate each organ coefficient, organ coefficient=Organ weight/body weight × 100% simultaneously.
A part of liver organization is taken to be dyed for HE simultaneously, a part of liver organization is used for oil red O stain.
3.4 liver lipids levels are determined
A pipe liver organization is taken in -80 DEG C of cold storage refrigerators.Tissue about 100mg is taken during detection, isopropanol, volume is added
1ml/50mg.Stood overnight after homogenate.Supernatant is taken after centrifugation in second day, wherein TC and TG contents are determined, the result conversion measured
As a result lipid content to contain in every kilogram of internal organs is converted into g/kg in terms of g.Molecular weight：Triglycerides 639g/mol；Total courage
Sterol 386.65g/mol.
3.5 liver homocysteines, determination of glutamyl-transpeptidase
A pipe liver organization is taken in -80 DEG C of cold storage refrigerators.Tissue about 100mg is taken during detection, blood stains are washed away with PBS.Cut
It is put into fritter in tissue grinder, adds 1ml PBS, homogenate is made, is subsequently placed in -20 DEG C overnight.By multigelation 2 times
After processing destruction cell membrane, tissue is homogenized and takes supernatant within 5 minutes in 4 DEG C of 5000g centrifugations, takes appropriate supernatant to test immediately.Survey
Method is determined according to ELISA method, is operated according to kit specification.
3.6 rat live body micro-CT are tested
One week before dissection of prevention administration group rat, carries out live body micro-CT experiments.Utilize Latheta LCT200
Toy CT, a micro-CT systems that multi-functional 3D scannings are carried out for animals such as rat, mouse and rabbits.Before experiment,
Each group rat first with 10% chloraldurate intraperitoneal injection of anesthesia 1-2h, is put into row abdomen simple scan in groove, to rat bone parameter, subcutaneously
The parameters such as fat, interior fat, fatty liver CT values are measured.The experiment is real in The Third Affiliated Hospital of Southern Medical University's medical science
Test research center progress.
4. result of the test
4.1 body weight curvilinear motions are compared
During prevention administration and therapeutic administratp, the changes of weight such as table 1~2 of each group rat different times and Fig. 2 institutes
Show.
During the prevention administration of table 1, the changes of weight results of each group rat different times (N=8)
During the therapeutic administratp of table 2, the changes of weight results of each group rat different times (N=8)
Interpretation of result：As shown in table 1~2 and accompanying drawing 2, normal group (SD groups) is compared with model group (HFD groups) rat body weight
Understand：The continued weight increase of model group, and with significant difference, show obesity rat model success.From composition prevention
The body weight interpretation of result of rat is understood after administration and therapeutic administratp：Composition high dose group (HQS-H groups), composition low dose group
(HQS-L groups) has preferable prevention effect to obesity, and administration group body weight is significantly lower than model group, close to normal group body
Weight, and Lipitor group (Lipitor groups) is substantially better than, Lipitor group body weight is dramatically increased, close to model group.Prevention group rat
MicroCT experiments are done within one week before administration, hence it is evident that feel that rat body weight increasess slowly, especially composition administration group rat body weight
Decline.
As shown in Figure 3, by counting each group rat averagely diet situation of every daily, it is known that feed each of high lipid food
Indifference between group rat diet situation.Show that the change of each group rat body weight is unrelated with dietary amount.
4.2 glycolipid biochemical indicators compare
4.2.1 prevention administration 7 weeks and therapeutic administratp after 9 weeks glycolipid biochemical indicator compare
Prevention administration 7 weeks and therapeutic administratp are after 9 weeks, each group rat FPG, TC, TG, LDL-C level change such as Fig. 4~5
It is shown.
From the point of view of the prevention administration 7 weeks and 9 weeks glycolipid results of therapeutic administratp shown in accompanying drawing 4~5, model group (HFD groups) and
Normal group (SD groups) is compared, and FPG, TC, TG, LDL-C level are significantly raised, and with significant difference.With model group phase
Than, composition high dose group (HQS-H groups), composition low dose group (HQS-L groups) have preferable hypoglycemic, effect for reducing fat, and
There is certain dose dependent.
4.2.2 prevention administration 12 weeks and therapeutic administratp after 14 weeks glycolipid biochemical indicator compare
Preventive administration 12 weeks and therapeutic administratp are after 14 weeks, and the change of each group rat FPG, TC, TG, LDL-C level is such as attached
Shown in Fig. 6~7.
From the point of view of the prevention administration 12 weeks and 14 weeks glycolipid results of therapeutic administratp shown in Fig. 6~7, model group (HFD groups) and
Normal group (SD groups) is compared, and FPG, TC, TG, LDL-C level are significantly raised, and with significant difference.With model group phase
Than, energy preferably hypoglycemic, the lipid-loweringing of composition high dose group (HQS-H groups), composition low dose group (HQS-L groups), and have
Doses dependence.And in terms of hypoglycemic, composition is better than Lipitor group.
4.3 homocysteines, glutamyl transpeptidase compare
Preventive administration 15 weeks and therapeutic are after 15 weeks, homocysteine level and paddy in each group rat liver
Aminoacyl transpeptidase level is as shown in Fig. 8~9.
Homocysteine (Hcy) is a kind of sulfur-containing amino acid in human body, is methionine and cysteine metabolic process
In important intermediate.Hcy too high is cardiovascular and cerebrovascular disease, osteoporosis, the hazards of the nervous system disease.Such as accompanying drawing
Shown in 8, by detecting Hcy levels in each group rat liver, model group (HFD groups) level of discovery is significantly raised, and composition it is high,
Low dose group (HQS-H groups, HQS-L groups) is significantly reduced, and showing the Rats adiposis hepatica of administration group is substantially improved.
Glutamyl transpeptidase (GTT1) has been one of liver function test project.As shown in accompanying drawing 9, by detecting liver
Middle GTT1 levels, it is known that model group level is significantly raised, and composition high and low dose group (HQS-H groups, HQS-L groups), Lipitor
Group (Lipitor groups) can be significantly reduced.
4.4 liver lipids compare
Preventive administration 15 weeks and therapeutic are after 15 weeks, and lipid (TC, TG) level is as schemed in each group rat liver
Shown in 10.
Lipid dystopy deposition refers to that body lipid is deposited in non-fat tissue, mostly occurs in liver, muscle and pancreas, most easily
The position of generation is liver.As shown in Figure 10, by detecting lipid in liver (TC, TG), model group (HFD groups) liver is found
Lipid is significantly raised, and administration group can significantly improve liver lipids deposition, and prevention group is more notable compared with treatment group.
4.5 liver oil red O stains compare
Preventive administration 15 weeks and therapeutic are after 15 weeks, and each group rat hepatocytes carry out the fat after oil red O stain
Fat denaturation contrast is as shown in figure 11.
As shown in Figure 11, nearly no fat drips in normal group liver cell.The fat drips of a large amount of bulla samples after model group dyeing,
Mutually fusion, and the high fat diet time is more long, fat drips are more obvious.Composition prevention high and low dose group (prevention HQS-H groups, prevention
HQS-L groups) hepatic cell fattydegeneration substantially mitigate, better than the high low dose group of composition treatment (treatment HQS-H groups, treatment
HQS-L groups), become apparent from high dose group degree of alleviation.The hepatic cell fattydegeneration and mould of composition height therapeutic dose group
Type group is compared, and is also substantially improved, and better than Lipitor group；Wherein, A represents normal group, and I representative model groups, K represents Li Pu
Appropriate group.
4.6 browns, white adipose coefficients comparison
4.6.1 white adipose coefficients comparison
Mammal mainly contains two kinds of white adipose (WAT) brown adipose tissue (BAT).And white adipose is generally wrapped
Include subcutaneous white adipose and internal organ white adipose.It is now recognized that subcutaneous white adipose and brown fat participate in maintaining human body energy
Stable state and the balance of metabolism, and internal organ white adipose then participates in the generation of metabolic disease.Subcutaneous white adipose mainly includes abdomen
Butt crack, oxter, thyroid gland side fat；Internal organ white adipose mainly includes epididymal adipose tissues, perirenal fat, mesenteric fat.Human body
Correlative study think, the correlation ratio of the risk factors of cardiovascular diseases such as internal organ white adipose and insulin resistance, diabetes
Subcutaneous white adipose is higher.Animal different parts adipose tissue form and function difference are inquired into, can preferably be Metabolic syndrome
The pathogenesis levied provides foundation.
Research finds, white adipose tissue by some physiological stimulations (cold expoure), hormonal stimulation (such as Irisin) with
And body receives after drug therapy (such as PPAR gamma agonists or beta-adrenergic are stimulated), may occur in which that brown fat phenotype is special
Levy, as fat drips diminish, it is excessive that line grain crosses number.Because white adipose milkproduct shows that energy balance switchs to energy by energy storage
Amount expenditure, thus as the novel targets of the metabolic diseases such as treatment obesity.
Preventive administration 15 weeks and therapeutic are after 15 weeks, and the epididymal adipose tissues and perirenal fat coefficient of each group rat are such as
Shown in table 3~4.
3 preventive administration of table 15 weeks and therapeutic are after 15 weeks, the epididymal adipose tissues of each group rat and perirenal fat system
Number
4 therapeutic of table 15 weeks and therapeutic are after 15 weeks, the epididymal adipose tissues of each group rat and perirenal fat system
Number
Interpretation of result：As shown in table 3~4, epididymal adipose tissues and perirenal fat are used as white adipose, composition high and low dose
Group (HQS-H groups, HQS-L groups) significantly reduces white adipose coefficient, and better than Lipitor group.
4.6.2 brown/white adipose coefficients comparison
Preventive administration 15 weeks and therapeutic be after 15 weeks, the brown fat of each group rat and white adipose such as
Shown in Figure 12~13.
As shown in accompanying drawing 12~13, by by the ratio between brown fat and white adipose it is also seen that come composition is high and low
Dosage group (HQS-H groups, HQS-L groups) can improve brown white ratio, better than Lipitor (Lipitor groups).
To sum up, epididymal adipose tissues coefficient, the perirenal fat coefficient for the obese rat model set up using pure high fat diet modeling
All apparently higher than normal rats.From administration, composition administration group can substantially reduce the epididymal adipose tissues system of animal pattern
Number, perirenal fat coefficient (reduction white adipose, the white ratio of raising palm fibre), and reduction is substantially, and to the base of white adipose milkproduct
Because influence is obvious；Substantial amounts of aliphatic acid, which is consumed, while reducing white adipose, improving brown fat serves reducing blood lipid
Act on (one of mechanism of reducing blood lipid).
4.7 bone weight coefficient ratios compare
As shown in Figure 14, by femur and the ratio of body weight, nothing between normal group (SD groups) and model group (HFD groups) is found
Difference, and composition high and low dose group (HQS-H groups, HQS-L groups), compared with model group, bone weight coefficient is significantly raised,
And with significant difference, show that composition has the effect for improving bone mass, and better than Lipitor (Lipitor groups).
4.8 living imagings observe the influence of medicine
Show medicine to skeleton, liver, fatty influence as shown in figures 15 to 18 by living imaging.Utilize Latheta
LCT200 carries out body scan, by calculating fat percentage, it has been found that compared with normal group, model group rats fat to live body rat
Fat rate and liver fat percentage are significantly raised, and with significant difference.Compared with model group, the fat percentage of the high low dose group of composition
Substantially reduced with liver fat rate, and with dose dependent.Total bone density to femur has also been lifted simultaneously.
As shown in Figure 16, can be with from figure which show the white adipose content of each group rat after prevention administration 14 weeks
Finding out the fat percentage of the high low dose group of fat-reducing liver-protecting composition substantially reduces.
As shown in Figure 17, after which show preventive administration 14 weeks, the fat content contrast in each group rat liver, from
The liver fat rate of the high low dose group of it can be seen from the figure that fat-reducing liver-protecting composition is substantially reduced.
As shown in Figure 18, after which show preventive administration 14 weeks, each group rat cortex bone density, cancellous bone density,
Total bone density (cortical bone density, cancellous bone density, total bone density that are followed successively by each group in Figure 18 from left to right).Can be with from figure
Find out that the high low dose group of fat-reducing liver-protecting composition has also been lifted to total bone density of femur.
The fat gene of composition for improved of the embodiment 2 comprising the Radix Astragali, the root of kudzu vine and the root bark of white mulberry
1st, experiment packet
This experiment is divided into 8 groups, and every group of difference is as follows：
A --- SD groups, N=8
B --- SD+GC groups, N=10
C --- HFD groups, N=8
D --- HFD+GC groups, N=12
The composition group of I --- HFD+GC+ embodiments 2, N=10
The composition group of J --- SD+GC+ embodiments 2, N=10
2. test method
SPF rank SD rats divide rat after regular grade Animal House adaptability is raised two weeks (about 200-220g) at random
For normal group, glucocorticoid group, high lipid food group, high fat sugaring cortin group, high fat sugaring cortin+composition
Group, glucocorticoid add composition group.Normal group, glucocorticoid group and glucocorticoid add composition group to feed with basis feeding
Material, other each groups are fed with high lipid food.In addition to normal group and high lipid food group give normal saline, remaining each group starts to fill
Stomach prednisone acetate 3.5mg/kg, once a day, while starting gastric infusion composition (2.96g/kg) after 1 hour, wherein yellow
Stilbene：The root of kudzu vine：The mass ratio of the root bark of white mulberry is 1:2:1, continuous 12 weeks.Thereafter, test operation is carried out in accordance with the following methods：
(1) extraction of total serum IgE
1. the white adipose and brown fat of animal are collected, preserving liquid with RNA preserves.Deposit in -80 DEG C of refrigerators.
2. thaw tissue, first takes out sample with tweezers, is put on filter paper and blots preservation liquid, weighs, after be transferred to it is another dry
In net 1.5ml Ep pipes, 1mltrizol is added, is shredded with small scissors in trizol liquid, anvil is broken in glass homogenizer
Be invisible to the naked eye bulky grain.5min is centrifuged in 10000rpm, carefully discards upper strata oily hyaline layer (fat deposit).
3. often pipe chlorination imitates 0.2ml, and acutely shaking mixes 15s, puts room temperature 5min and is allowed to be layered, 4 DEG C of 10000 × g centrifugations
5min, carefully moves to upper strata aqueous phase in another 1.5ml centrifuge tubes.
4. often pipe adds 0.5ml isopropanols, and room temperature places 10min, and 4 DEG C of 10000 × g centrifuge 10min.Carefully by upper strata
Clear liquid is discarded, and precipitation is washed with 70% ethanol 1ml, and 4 DEG C of 5000 × g centrifuge 5min, abandon supernatant, room temperature, which is placed, makes ethanol complete
Volatilization, ttom of pipe visible white dot is RNA.
5. 30 μ l are added without RNase water in precipitating, 58 DEG C of water-bath 10min make precipitation fully dissolve.
(2) detection of RNA concentration, purity
With DU800 nucleic acid/protein analyzer at wavelength 260nm and 280nm respectively determine RNA samples OD-A260 and
A280 (the A260/ A280 ratios of the high sample of RNA purity>1.7), and RNA concentration is measured.Take and determined on a small quantity with nucleic acid-protein
Instrument determines A260, calculates rna content.And it is 1.8~2.0 to determine A260/A280, it was demonstrated that RNA purity.Remaining puts -80 DEG C of jellies
Deposit standby.
(3) RT synthesizes cDNA
The RNA sample extracted using upper step, RT reactions are carried out with reference to RT reagents specification.RT reaction systems such as following table institute
Show.
* according to added by being calculated RNA concentration the μ g of total serum IgE amount 3.0 RNA volumes, then adjust RNas-free ultrapure water consumption, make
Reaction cumulative volume is 20 μ l.
Following thermocycling program is set to be reacted (following table) in RT-PCR thermal cyclers：
After reaction terminates, gained cDNA products put -20 DEG C of preservations.
(4)Real time PCR
1. PCR primer design and synthesis
Primer is designed according to real time PCR primers design principle.NCBI GenBank databases are retrieved, it is designed
Primer is directed to different extrons, the calibrating cdna compareed using β-actin as internal reference respectively.Using Primer
Premier5.0 softwares separately design MCP-1, UCP-1, PRDM16, Cidea and β-actin PCR primer, different primers
Sequence is shown in Table 15, and all PCR primers are synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
2. Real time PCR reaction products are verified
Reaction system (following table) is formulated as follows by the operational manual of SYBR qPCR Mix kits
Real time PCR are carried out with ABI7500 type real time PCR instruments, amplification condition is as shown in the table：
3. the expression of Real time PCR testing goals gene and internal reference β-actin genes in each group adipose tissue
In 50 μ l reaction systems, contain template cDNA200ng, remaining reacted constituent, amplification condition and melt curve analysis
Setting with product confirmatory experiment.MCP-1, UCP-1, PRDM16, Cidea and β-actin DNA fragmentation are expanded respectively.Adopt
Data analysis is carried out to real time PCR results with 2- △ △ CT methods, the numerical value of wherein Normal group is 1.
3. result of the test
UCP-1 gene expressions in 3.1 brown adipose tissues
UCP-1 genes expressed in abundance in brown adipose tissue, is seldom expressed in white adipose tissue, is brown fat
Cell-specific genes.As shown in Figure 19, in addition to high lipid food group, remaining each group in UCP-1 gene expressions all substantially under
Drop, wherein the UCP-1 gene expressions of I groups (the composition group of HFD+GC+ embodiments 2) are apparently higher than D groups (HFD+GC groups), explanation
Composition can promote brown fat cell-specific genes UCP-1 expression, illustrate that composition has product in resistance obesity
Pole meaning.
Cidea gene expressions in 3.2 brown adipose tissues
As shown in Figure 20, I groups (the composition group of HFD+GC+ embodiments 2) substantially rise in Cidea gene expressions, high
In other each groups, illustrate that composition has positive effect in resistance obesity.
MCP-1 gene expressions in 3.3 white adipose tissues
As shown in Figure 21, compared with normal group, remaining each group all substantially rises in MCP-1 gene expressions.Compared with D groups
(high lipid food sugaring cortin group), composition administration group (I, J group) is decreased obviously in MCP-1 gene expressions.
PRDM16 gene expressions in 3.4 brown adipose tissues
Accompanying drawing 22 shows that PRDM16 transcription factors play an important role in regulation and control brown fat and sarcoblast conversion, are
Keep necessary to brown fat phenotype, can also promote brown fat formation, energy expenditure.
In summary, composition is obvious to the effect gene of white adipose milkproduct.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than the present invention is protected
The limitation of scope is protected, although being explained in detail with reference to preferred embodiment to the present invention, one of ordinary skill in the art should
Understand, technical scheme can be modified or equivalent substitution, without departing from the essence of technical solution of the present invention
And scope.
Claims (14)
1. a kind of purposes of composition in food, medicine and the health products for preparing prevention or treatment obesity, wherein, institute
State composition and include the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：The root of kudzu vine：Sang Bai
Skin=(1~2)：(1~2)：(0~2).
2. purposes as claimed in claim 1, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：Pueraria lobota
Root：The root bark of white mulberry=2:1:1.
3. purposes as claimed in claim 1, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：Pueraria lobota
Root：The root bark of white mulberry=1:2:1.
4. purposes as claimed in claim 1, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：Pueraria lobota
Root：The root bark of white mulberry=1:1:2.
5. purposes as claimed in claim 1, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：Pueraria lobota
Root：The root bark of white mulberry=1:1:1.
6. purposes as claimed in claim 1, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：Pueraria lobota
Root：The root bark of white mulberry=2:1:0.
7. purposes as claimed in claim 1, it is characterised in that the composition is accumulated by reducing the white adipose in obesity
Tire out to prevent or treat obesity.
8. purposes as claimed in claim 1, it is characterised in that the composition can reduce the Guang of homotype half caused by obesity
Propylhomoserin is raised.
9. a kind of composition is in food, medicine and the health products for preparing prevention or treatment hyperhomocysteinemiainjury
Purposes, wherein, the composition includes the Radix Astragali, the root of kudzu vine and the root bark of white mulberry, and the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is Huang
Stilbene：The root of kudzu vine：The root bark of white mulberry=(1~2)：(1~2)：(0~2).
10. purposes as claimed in claim 9, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：
The root of kudzu vine：The root bark of white mulberry=2:1:1.
11. purposes as claimed in claim 9, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：
The root of kudzu vine：The root bark of white mulberry=1:2:1.
12. purposes as claimed in claim 9, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：
The root of kudzu vine：The root bark of white mulberry=1:1:2.
13. purposes as claimed in claim 9, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：
The root of kudzu vine：The root bark of white mulberry=1:1:1.
14. purposes as claimed in claim 9, it is characterised in that the mass ratio of the Radix Astragali, the root of kudzu vine and the root bark of white mulberry is the Radix Astragali：
The root of kudzu vine：The root bark of white mulberry=2:1:0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710223954.2A CN107114764B (en) | 2017-04-07 | 2017-04-07 | New application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710223954.2A CN107114764B (en) | 2017-04-07 | 2017-04-07 | New application of composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107114764A true CN107114764A (en) | 2017-09-01 |
| CN107114764B CN107114764B (en) | 2020-11-10 |
Family
ID=59724673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710223954.2A Active CN107114764B (en) | 2017-04-07 | 2017-04-07 | New application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107114764B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107854522A (en) * | 2017-09-13 | 2018-03-30 | 北京宜生堂医药科技研究有限公司 | A kind of composition and its production and use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688295A (en) * | 2012-06-14 | 2012-09-26 | 上海中医药大学 | Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof |
-
2017
- 2017-04-07 CN CN201710223954.2A patent/CN107114764B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688295A (en) * | 2012-06-14 | 2012-09-26 | 上海中医药大学 | Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王春怡: "黄芪散干预2型糖尿病胰岛素抵抗机制及制剂基础研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107854522A (en) * | 2017-09-13 | 2018-03-30 | 北京宜生堂医药科技研究有限公司 | A kind of composition and its production and use |
| CN107854522B (en) * | 2017-09-13 | 2020-10-30 | 北京宜生堂医药科技研究有限公司 | Composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107114764B (en) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| CN102578030B (en) | Selenium-enriched ground beetle breeding method, capsules of freeze-dried powder of selenium-enriched ground beetles, protein hydrolysate of selenium-enriched ground beetles, and medicinal uses of selenium-enriched ground beetles | |
| WO2017181857A1 (en) | Composition for fat reduction and liver protection, and application thereof | |
| CN109432315A (en) | Application of the cogongrass rhizome extractive as active constituent in the product that preparation relieves fatigue | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN107114764A (en) | A kind of new application of composition | |
| CN107823286A (en) | Potentilla viscosa Donn extract and its application | |
| CN103550281A (en) | Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof | |
| KR100542809B1 (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
| CA3022247A1 (en) | Composition for treating diabetic disease | |
| CN101554386B (en) | Medicine composition for curing hepatic disease and preparation method thereof | |
| CN1951380A (en) | Medical usage of salvianolic acid B salt and total salvianolic acid | |
| CN106924549A (en) | A kind of preparation method of composition and extract with benefiting qi and nourishing blood function and application | |
| CN110150229A (en) | A kind of production method of diabetes tendon degeneration necrosis disease model rodent | |
| KR20040062832A (en) | Pharmaceutical composition for medical treatments and prevention of obesity including herbal medicine extracts | |
| CN104001156A (en) | Application of eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in treatment of liver injury | |
| CN107714817A (en) | A kind of Chinese medicine composition for treating diabetic nephropathy | |
| CN104968342B (en) | Sulforaphane for the insulin resistance for treating or reducing liver | |
| Ambadasu et al. | Effect of Caralluma Fimbriata extract on appetite, body weight and lipid profile in cafeteria diet-induced obesity in rats. | |
| CN102716182A (en) | Semen cassiae extract for treating nonalcoholic fatty liver diseases as well as preparation method and application of semen cassiae extract | |
| CN107625777A (en) | Purposes of the rhodioside in complement inhibitor medicine is prepared | |
| CN110302380B (en) | Application of litchis water extract radiotherapy sensitizer | |
| CN107961382A (en) | Applications of the miR-1252 in the medicine for preparing treatment atopic dermatitis | |
| CN101352475A (en) | Use of honeysuckle aqueous extract in preparing medicament for improving insulin resistance | |
| CN103816549B (en) | 3 kinds of microRNA in tea tree source and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |